Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at Jefferies Group lifted their FY2020 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Thursday. Jefferies Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings per share of $18.59 for the year, up from their previous forecast of $17.85. Jefferies Group has a “Hold” rating and a $500.00 price target on the stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same period last year, the firm earned $2.82 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: “Brokers Set Expectations for Regeneron Pharmaceuticals, Inc.’s FY2020 Earnings (REGN)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/11/brokers-set-expectations-for-regeneron-pharmaceuticals-inc-s-fy2020-earnings-regn.html.

Several other research analysts have also recently weighed in on REGN. Canaccord Genuity set a $484.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 20th. BTIG Research restated a “buy” rating and issued a $540.00 price objective (up from $480.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, June 30th. BidaskClub cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Bank of America Corporation restated a “buy” rating and issued a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Citigroup Inc. upped their price objective on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average target price of $489.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 2.29% during trading on Monday, reaching $450.57. 650,713 shares of the company’s stock traded hands. The stock has a market cap of $47.03 billion, a price-to-earnings ratio of 45.19 and a beta of 1.62. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The company’s 50 day moving average is $460.12 and its 200-day moving average is $454.49.

In related news, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the completion of the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,296,456.81. The disclosure for this sale can be found here. Insiders have sold 89,468 shares of company stock valued at $42,312,448 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. BlackRock Inc. increased its holdings in Regeneron Pharmaceuticals by 3,331.5% in the 1st quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Regeneron Pharmaceuticals by 15,495.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock worth $767,637,000 after buying an additional 1,552,948 shares in the last quarter. Jennison Associates LLC increased its holdings in Regeneron Pharmaceuticals by 74.1% in the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock worth $634,977,000 after buying an additional 550,247 shares in the last quarter. Janus Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 58.5% in the 1st quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares in the last quarter. Finally, FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares in the last quarter. Institutional investors own 67.41% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.